VaxcytePCVX
PCVX
About: Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
Employees: 254
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
305% more first-time investments, than exits
New positions opened: 85 | Existing positions closed: 21
66% more capital invested
Capital invested by funds: $9.4B [Q2] → $15.6B (+$6.22B) [Q3]
53% more funds holding in top 10
Funds holding in top 10: 15 [Q2] → 23 (+8) [Q3]
45% more repeat investments, than reductions
Existing positions increased: 126 | Existing positions reduced: 87
42% more call options, than puts
Call options by funds: $94M | Put options by funds: $66.3M
23% more funds holding
Funds holding: 263 [Q2] → 324 (+61) [Q3]
2.04% less ownership
Funds ownership: 114.38% [Q2] → 112.33% (-2.04%) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$135
56%
upside
Avg. target
$138
59%
upside
High target
$140
62%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Goldman Sachs Chris Shibutani 50% 1-year accuracy 5 / 10 met price target | 56%upside $135 | Buy Initiated | 20 Dec 2024 |
Needham Joseph Stringer 27% 1-year accuracy 33 / 123 met price target | 62%upside $140 | Buy Reiterated | 6 Nov 2024 |
Financial journalist opinion
Based on 4 articles about PCVX published over the past 30 days
Neutral
GlobeNewsWire
5 days ago
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
SAN CARLOS, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference in New York on Thursday, February 6, 2025 at 9:30 a.m. ET / 6:30 a.m. PT.
Neutral
GlobeNewsWire
5 days ago
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Positive
Seeking Alpha
2 weeks ago
Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy
Vaxcyte's stock surged 68% since August 2023, driven by progress with its pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31. VAX-31, covering 95.6% of serotypes, has been selected over VAX-24 for Phase 3 trials, with topline data expected in 2026. Vaxcyte's robust financial position, with over $3 billion in cash and investments, supports its strategic flexibility and extended timelines.
Neutral
PRNewsWire
4 weeks ago
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Neutral
GlobeNewsWire
1 month ago
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Neutral
GlobeNewsWire
2 months ago
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose Approximately Nine Months Later -- -- VAX-31 is Designed to Cover Approximately 94% of Invasive Pneumococcal Disease and Approximately 93% of Acute Otitis Media in U.S. Children Under Five --
Neutral
GlobeNewsWire
2 months ago
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
-- VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 -- -- VAX-31 Adult Indication: Breakthrough Therapy Designation Granted by FDA; Company Plans to Initiate Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 --
Neutral
GlobeNewsWire
3 months ago
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, in Adults Aged 50 and Older -- -- PCV Adult Indication: VAX-31 Selected to Advance to Phase 3 Program; Initiation of Phase 3 Pivotal, Non-Inferiority Study Expected by Mid-2025 and Announcement of Topline Safety, Tolerability and Immunogenicity Data in 2026 --
Neutral
GlobeNewsWire
4 months ago
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT.
Positive
Seeking Alpha
4 months ago
Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027
Vaxcyte's XpressCF platform enables the development of broad-spectrum vaccines, overcoming the limitations of traditional cell-based approaches. VAX-31 and VAX-24 are Vaxcyte's key value drivers. They target invasive pneumococcal disease (IPD) with superior coverage compared to competitors. VAX-31's Phase 1/2 results demonstrated a favorable safety profile and strong immunogenicity, positioning it for Phase 3 trials by mid-2025.
Charts implemented using Lightweight Charts™